Reuters: Regulatory News: Vermillion gets US patent on cancer test methods

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Vermillion gets US patent on cancer test methods Mar 28th 2012, 13:22 March 28 | Wed Mar 28, 2012 9:22am EDT March 28 (Reuters) - Vermillion Inc said its methods for diagnosing ovarian cancer received a patent in the United States, sending its shares up 18 percent in premarket trade. The United States Patent and Trademark Office granted a patent on the use of Protein C Inhibitor in tests to measure the presence or progress of ovarian cancer, Vermillion said. "The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1," Chief Science Officer Donald Munroe said in a statement. In 2009, the U.S. Food and Drug Administration approved Vermillion's blood test, OVA1, for pre-surgical ovarian cancer diagnosis. Shares of the company were up at $2.08 in trading before the bell. They closed at $1.77 on Tuesday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions